HAB Pharma and Signature Phytochemicals have completed their merger, creating an entity with a consolidated turnover of about ₹600 crore.
Finalized in March 2026, the merger was undertaken to streamline operations, harmonize corporate systems, and strengthen governance, a note from HAB Pharma said.
HAB Pharmaceuticals has manufacturing capabilities producing antibiotics,
NSAIDs, and cardiovascular drugs. Signature Phytochemical Industries specializes in manufacturing and exporting tablets, capsules, and creams, it added.
The merger expands the combined entity’s manufacturing, research, and development capabilities, with a focus on specialty drugs for oncology, autoimmune disorders, chronic
conditions, and rare diseases, it said. The merged entity is now targeting markets in Latin America, Central Asia, and Southeast Asia.
HAB Pharmaceuticals is commissioning two new manufacturing plants – a sterile facility focused on semaglutide, prefilled syringes, injectables, vials, and lyophilized products, and a fully automated closed-loop oral solid dosage (OSD) plant, it said. Both plants are expected to commence commercial production by August 2026.
Saurabh Agarwal, Director at HAB Pharma, said, “Our focus on innovation, niche products, and increasing our export and R&D capabilities will solidify the company’s position in the pharmaceutical industry, differentiating us through a diversified portfolio and a rapid go-to-market strategy.”